Govt extends HLL Lifecare bid submission deadline till February 28

Published On 2022-01-22 11:26 GMT   |   Update On 2022-01-22 11:26 GMT

New Delhi: The government has extended the deadline by about a month till February 28 for prospective buyers to submit the expression of interest (EoI) for strategic sale-bound HLL Lifecare.

The Department of Investment and Public Asset Management (DIPAM) had on December 14 invited preliminary bids for selling the government's 100 per cent stake in the health sector CPSE. The last date for expression of interest (EoI) was January 31.

In view of the prevailing situation arising out of the COVID-19 pandemic and on the request of the interested bidders, the late date for submission of EoIs is extended to February 28, DIPAM said in a notice on its website.

Also Read:MSN to launch generic anti-COVID pill Molnupiravir

The due date for intimation to the qualified interested bidders (QIBs) by the DIPAM has also been extended by a month till March 14.

HLL, a CPSE under the Ministry of Health and Family Welfare, is involved in manufacturing and marketing a range of contraceptives, women's healthcare products, hospital supplies as well as other pharmaceutical products.

HLL is also engaged in providing healthcare and diagnostic services, consultancy and contract services for healthcare infrastructure projects and consultancy services for procurement of medical equipment and devices in the healthcare sector and caters to both domestic and international markets.

As of March 31, 2021, HLL's authorised capital was Rs 300 crore and its paid-up share capital was Rs 15.53 crore.

With this deadline extension, the strategic sale of HLL Lifecare is now expected to spill over to the next financial year beginning April 1.

Also Read:Pfizer oral COVID pill Paxlovid approved in Canada


Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News